Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.

Xp11.2 translocation renal cell carcinoma (RCC) is a rare malignancy in adults. There is currently no consensus regarding the appropriate treatment for recurring or metastatic Xp11.2 translocation RCC. There is also limited information on the efficacy of molecular targeted therapy, especially mammalian target of rapamycin (mTOR) inhibitors, for Xp11.2 translocation RCC. We report a case of recurrent Xp11.2 translocation RCC occurring 12 years after tumor resection and lymphadenectomy for the original tumor. The patient achieved long-term survival with combined modality therapy comprised of surgery and administration of various molecular targeted agents, including tyrosine kinase and mTOR inhibitors. This case suggests that molecular targeted therapy, including mTOR inhibitors, might represent a useful and effective therapeutic tool for advanced Xp11.2 translocation RCC. (C) 2016 Elsevier Inc. All rights reserved.